

NDA 202107/S-008

SUPPLEMENT APPROVAL

Corcept Therapeutics Attention: Susan Rinne Vice President, Corporate Regulatory Affairs 149 Commonwealth Drive Menlo Park, CA 94025

Dear Ms. Rinne:

Please refer to your supplemental new drug application (sNDA) dated and received March 30, 2018, and your amendments, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Korlym (mifepristone) tablets, 300 mg.

This Prior Approval supplemental new drug application provides for the revisions to the prescribing information (PI) to include the results from Study C1073-38 titled, *A Phase 1, Open-Label, Drug-drug Interaction Study in Healthy Subjects to Determine the Effects of a Strong Inhibitor (Itraconazole) of Cytochrome P450 3A on Exposure to Mifepristone and Its Metabolites.* Specific sections of the PI impacted by this information are:

- Dosage and Administration section, 2.4 Concomitant Administration with CYP3A4 Inhibitors subsection,
- 2. Warnings and Precautions section, 5.6 Use of Strong CYP3A4 inhibitors subsection
- 3. Drug Interactions section, 7.2 CYP3A4 Inhibitors subsection
- 4. Clinical Pharmacology section, 12.3 Pharmacokinetics subsection

The supplement also provides for revisions to the PI to comply with the Pregnancy Lactation Labeling Rule (PLLR).

The Medication Guide (MG) has also been revised to be consistent with the PLLR revisions to the PI and other editorial revisions.

### **APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

## **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(I)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.<sup>1</sup> Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, and Medication Guide), with the addition of any labeling changes in pending "Changes Being

<sup>1</sup> http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm



NDA 202107/S-008 Page 2

Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry SPL Standard for Content of Labeling Technical Qs and As.<sup>2</sup>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(I)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

#### REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

### PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the Prescribing Information to:

OPDP Regulatory Project Manager Food and Drug Administration Center for Drug Evaluation and Research Office of Prescription Drug Promotion (OPDP) 5901-B Ammendale Road Beltsville, MD 20705-1266

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft

<sup>&</sup>lt;sup>2</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <a href="https://www.fda.gov/RegulatoryInformation/Guidances/default.htm">https://www.fda.gov/RegulatoryInformation/Guidances/default.htm</a>.



Guidance for industry Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs.<sup>3</sup>

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at FDA.gov.<sup>4</sup> Information and Instructions for completing the form can be found at FDA.gov.<sup>5</sup> For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see FDA.gov.<sup>6</sup>

# **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Jennifer Johnson, Regulatory Project Manager, at 301-796-2194.

Sincerely,


{See appended electronic signature page}

Lisa B. Yanoff, MD Director (Acting) Division of Metabolism and Endocrinology Products Office of Drug Evaluation II Center for Drug Evaluation and Research

#### **ENCLOSURES:**

- Content of Labeling
  - Prescribing Information
  - Medication Guide

<sup>&</sup>lt;sup>6</sup> http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm





<sup>&</sup>lt;sup>3</sup> When final, this guidance will represent the FDA's current thinking on this topic. For the most recent version of a guidance, check the FDA guidance web page at <a href="https://www.fda.gov/RegulatoryInformation/Guidances/default.htm">https://www.fda.gov/RegulatoryInformation/Guidances/default.htm</a>.

<sup>&</sup>lt;sup>4</sup> http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf

http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf

\_\_\_\_\_

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

\_\_\_\_\_

/s/

LISA B YANOFF 11/05/2019 03:05:54 PM

